Test Price
2,800 AED✅ Home Collection Available
CD19 Gene Common Variable Immunodeficiency Type 3 (CVID3) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Diagnostic Accuracy: Greater than 99.9% sensitivity for pathogenic and likely pathogenic variants in the CD19 gene, validated by ClinVar and ACMG criteria using Next-Generation Sequencing (NGS) in an ISO 9001:2015 certified laboratory (Certificate INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy with temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM across all UAE emirates, including FTA card micro-sampling for infants and remote areas.
- Genetic Counselling: Mandatory pre-test counselling and post-result telephone consultation with a Consultant Medical Genetics professional to interpret the report and guide clinical decision-making.
- Insurance Facilitation: Immediate upfront insurance coverage verification via WhatsApp at +971 54 548 8731 with direct billing support for eligible policies.
Test Overview & Methodology
This molecular diagnostic test employs Next-Generation Sequencing (Illumina platform) to comprehensively scan the entire coding region and intron-exon boundaries of the CD19 gene. Copy number variation (CNV) analysis is integrated into the bioinformatics pipeline, and all reported variants are confirmed by Sanger sequencing. The test establishes a definitive genetic diagnosis for common variable immunodeficiency type 3 (CVID3), a primary B-cell disorder characterised by recurrent sinopulmonary infections, autoimmune manifestations, and humoral immune deficiency. Clinical correlation with quantitative immunoglobulins, B-cell subsets, and family pedigree remains essential for complete diagnostic integration.
| Feature | Our Test: NGS CD19 Gene Sequencing | Closest Alternative: Serum Immunoglobulin Panel |
|---|---|---|
| Diagnostic Precision | >99.9% sensitivity for pathogenic / likely pathogenic variants (ClinVar/ACMG) | ~70% sensitivity for CVID screening; non-specific |
| Methodology | Next-Generation Sequencing (Illumina) with CNV analysis; Sanger confirmation | Nephelometry / Turbidimetry (IgG, IgA, IgM) |
| Turnaround Time | 21–28 Days (comprehensive report with clinical commentary) | 1–2 Days |
| Clinical Utility | Gold-standard molecular diagnosis; targeted therapy guidance, family cascade screening, prognostic stratification | Quantifies immunoglobulin levels; cannot differentiate genetic from acquired causes |
Physician Insight & Safety Protocols
“From a clinical genetics perspective, confirming a CD19 variant provides the cornerstone for precision management in CVID3. However, a genetic finding must always be interpreted alongside the complete immunological profile, infection history, and family pedigree. A positive result is not an endpoint but a gateway to tailored therapy and proactive family screening. As you navigate this diagnostic journey, please remember that immunoglobulin replacement therapy and immunomodulatory medications must never be paused or altered without explicit guidance from your treating immunologist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory on Medication Continuity
Critical Medication Advisory
Patients undergoing CD19 genetic testing should continue all prescribed therapies without interruption. The test does not require fasting, and no medication changes are necessary for sample collection. If you are taking anticoagulant therapy, inform the phlebotomist prior to venipuncture. Never discontinue immunoglobulin replacement, immunosuppressive agents, or any prescribed treatment based on preliminary genetic findings. Only your treating physician is authorised to adjust your therapeutic regimen.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion: Active febrile illness or acute infection at the time of home collection — reschedule until the patient is afebrile for a minimum of 48 hours.
- Exclusion: Known severe coagulopathy or platelet count below 30 × 10⁹/L — requires physician clearance before venipuncture can proceed.
- Emergency Red Flag: If during or immediately after sample collection the patient develops sudden chest pain, severe dyspnoea, angioedema, or loss of consciousness, call 998 or 999 without delay and alert the attending phlebotomist.
- Paediatric Consideration: Written informed consent from a legal guardian is mandatory for minors. Infants under 2.5 kg require neonatologist approval for FTA card blood collection.
Patient FAQ & Clinical Guidance
1. What exactly does the CD19 NGS test detect, and who should consider it?
This genetic test identifies disease-causing variants across the entire CD19 gene, providing a definitive molecular diagnosis for common variable immunodeficiency type 3 (CVID3). It is indicated for individuals with recurrent sinopulmonary infections, unexplained autoimmune cytopenias, dermatological autoimmune conditions such as vitiligo-like lesions, or a documented family history of CVID. A mandatory pre-test genetic counselling session is required to construct a detailed three-generation pedigree and establish clinical context before testing proceeds.
2. How is the sample collected, and is a physician referral necessary?
Sample collection is performed by our certified mobile phlebotomy team using whole blood (EDTA), extracted DNA, or a single blood drop on an FTA card — all transported under stringent cold-chain conditions. While a physician referral is strongly recommended for proper clinical framing, individuals may self-request testing after completing a mandatory genetic counselling session. The service operates 8 AM to 11 PM, seven days a week, and results are delivered within three to four weeks.
3. I have received a positive result – what are the subsequent steps?
A positive CD19 variant should be reviewed with a clinical immunologist to correlate the genetic finding with your immune profile, quantitative immunoglobulins, B-cell subsets, and vaccine response studies. Cascade screening of first-degree relatives is strongly advised; our genetic counselling team can coordinate family testing at a reduced rate. Therapeutic decisions — including immunoglobulin replacement or immunosuppressive therapy — must never be modified without direct consultation with your treating specialist.
UAE Regulatory & Data Privacy Adherence
This diagnostic service operates in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring that all genetic and clinical data are processed, stored, and transmitted under strict confidentiality safeguards. Laboratory operations also adhere to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which governs the security of health information systems. Clinical safety and patient consent protocols are aligned with Federal Decree-Law No. 4 of 2016 on Medical Liability. The laboratory holds ISO 9001:2015 certification (Certificate INT/EGQ/2509DA/3139), and all genetic counselling services are provided by DHA-licensed professionals. This page is intended for informational purposes only and does not constitute a medical diagnosis or treatment recommendation.
Clinical & Logistical Metadata
| Test Name | CD19 Gene Common Variable Immunodeficiency Type 3 (CVID3) Genetic Test (NGS) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 21–28 Days (3–4 Weeks) |
| Sample Type / Matrix | Whole blood (EDTA), extracted DNA, or one drop of blood on FTA card |
| Methodology Used | Next-Generation Sequencing (Illumina), CNV analysis, Sanger confirmation |
| ICD-10-CM Code | D83.8 |
| LOINC Code | 94233-9 |
| DHA Facility License & Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians